Novo Nordisk gains EU approval for FlexTouch®

Novo NordiskNovo Nordisk has been granted approval by the European Commission for the new prefilled insulin pen - FlexTouch®. The approval is for NovoRapid® (insulin aspart) and Levemir® (insulin detemir) - both modern insulins currently delivered in FlexPen®. FlexTouch® is the latest prefilled delivery system from Novo Nordisk which offers a new insulin injection experience for users. Current insulin pens require users to inject their insulin in a traditional way - using the force of their thumb to push the button. For some patients this can be difficult.

"Simplicity is the key requirement for any insulin pen," says Dr Tim Bailey, MD, AMCR Institute, US, "everyone benefits when the pen is simple and easy to use - patients, doctors and nurses educating the patients."

FlexTouch® has an easy-touch button which requires very little force to inject the insulin - at any dose. "As FlexTouch® requires a very small force to inject it means that almost any patient can use it" remarks Dr Bailey.

Launch timing of FlexTouch® in specific EU countries is pending local negotiations in each country.

About FlexTouch®
FlexTouch® is a prefilled insulin pen containing 300 units of insulin. It doses in 1 unit increments, from 1 to 80 units. It is compatible with NovoTwist® needles.

NovoTwist® comes in 5 mm (32G Tip) and 8 mm (30G) versions. An audible and tactile 'click' confirms attachment of the needle.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.